Or, you know, they needed more cash in order push through the next bit of the trial before they're in a position to release results.
You missed this bit:
"The units are being sold at a public offering price of $4.80 per unit. Each unit consists of one share of common stock and a warrant to purchase 0.5 of a share of common stock at an exercise price of $6.00 per share. The shares of common stock and warrants are immediately separable and will be issued separately. The underwriters will purchase the units at a price of $4.488 per unit, representing a 6.5% discount from the public offering price"
That is in regards to the original offering, not the over-allotment. That's where the underwriters make their money for underwriting. So it's not an initial incentive, and the shares are still offered to the public at the $4.80 price. This is exactly the way these things normally work.
Oh, and we're only below "average volume" if you only average the past week. We're still way above the average volume for any longer time period.
Where did you get that information? It doesn't match the article, which lists an extra 3.525 million for the 734,374 shares, which works out to exactly $4.80 per share.
Yes, that's how biotech startup dilutions work. We're giving them money to complete their trials, they (hopefully) pay us back, many-fold, when a successful trial sends the share price through the roof.
Anyone who thinks they are going to get approval out of the P1 trial for direct doesn't understand the system. They are proceeding directly into a P2 trial that is more focused on specific cancers and even that is unlikely to produce an early approval. That was written into the study design.
However, PFS and OS from the current standard of care does provide some basis for comparison. It's not perfect, but if the numbers are hugely better than the current best treatment, it will be a strong indicator of function. That might point the way towards early approval, or at least an accelerated PIII trial.
I'm still pretty happy. I got in at $3.50. Given last weeks increase, I'm still up 40% and the company has the cash to go forward, hopefully all the way through results on the current trials.
The trial is open for all solid tumors. As far as which ones are actually being enrolled, that's an unknown at this point.
If he's able to influence thousands of people to sell or buy millions of shares, I don't think he cares that much.
Alternatively, he just wrote an article that happened to align with a run-up he had nothing to do with.
Except that it still costs $6.00 to exercise the warrant. So the net cost is 2*$4.80+1*$6.00/3=$5.20/sharer assuming the warrants are ever fully exercised.
Double check how warrants work. If the investor chooses to exercise the warrant, they still have to pay the face price at the time of exercise. So it's two shares at $4.90 and one potential share at $6.00.
Um, not just spam, but stupid spam. Every major tobacco company has an E-cigarette line, and they're all publicly traded.
Cancer is never really considered "cured". There is always believed to be a chance of recurrence, even in 10 year or longer survivors. This is especially true when you have a relatively low number of patients that have used a treatment. They can't talk about longer term survival rates, since they have literally only a few patients that have taken the treatment over ten years ago. Maybe its a true cure, maybe its an imperfect cure, maybe it only treats for a certain period of time. Until they have more information, those are open questions.